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Previews
a large 2 MDa multiprotein complex that includesThe BRCA2-EMSY Connection:
BRAF35, an HMG domain-containing component of theImplications for Breast SWI/SNF complex; and its N terminus appears to have
intrinsic histone acetyl transferase activity (reviewed inand Ovarian Tumorigenesis
Venkitaraman, 2002). These interactions may reflect a
role for BRCA2 in modulating access to chromatin during
double-strand break repair. However, a role for BRCA2
In this issue, Hughes-Davies et al. describe a novel in transcriptional regulation has also been proposed,
gene product, EMSY, which suppresses the transacti- based on the ability of the third exon to mediate trans-
vational activity of BRCA2. EMSY is located within an activation in reporter assays (Milner et al., 1997). Specific
amplicon in sporadic breast and ovarian cancers, sug- transcriptional targets for BRCA2 have not been iden-
gesting that its overexpression may mimic the effects tified.
of BRCA2 inactivation. The implications for BRCA2 In this issue, Hughes-Davies et al. (2003) now present
evidence supporting a role for BRCA2 in chromatin re-function are discussed.
modeling and potentially in transcriptional regulation.
They identify a novel protein, EMSY, which binds to exonInherited mutations in either BRCA1 or BRCA2 account
3 of BRCA2 and suppresses activation of a reporterfor 75% of familial breast-ovarian cancer. In these
construct by a BRCA2-GAL4 fusion protein. A role forcases, a heterozygous germ-line mutation, which most
EMSY in the DNA damage response is supported by itscommonly results in premature protein truncation, is
colocalization with the DNA damage marker phospho-accompanied by somatic loss of the remaining wild-
histone 2AX (and presumably with BRCA2 as well) withintype allele and hence complete loss of gene function
characteristic nuclear structures in irradiated cells.(Venkitaraman, 2002). However, the virtual absence of
EMSY encodes a protein of 1,322 amino acids, with noBRCA1 or BRCA2 mutations in sporadic breast and
obvious function. However, it has a newly describedovarian cancers is unexplained. Tumorigenesis associ-
“ENT” domain that is shared with plant proteins con-ated with inactivation of the BRCA genes might depend
taining a newly coined “Royal Family” domain, whichon an organ-specific developmental window, and hence
includes the well characterized chromodomain impli-occur only in the context of inherited cancer predisposi-
cated in the recognition of methylated lysines withintion. Alternatively, distinct mechanisms targeting the
histones and in chromatin regulation (Hughes-Davies etBRCA pathways may operate in sporadic cases. Silenc-
al., 2003). While it does not have a Royal Family motif,ing of BRCA1 through promoter methylation has been
EMSY interacts with two proteins that do, HP1- andsuggested in some studies. The observation that other
BS69. Taken together, these data strengthen the linkcomponents of the BRCA pathways may be targeted
between BRCA2 and proteins implicated in chromatin
by genetic events in sporadic cancer has important im-
remodeling. Whether this reflects a direct role for BRCA2
plications for understanding the most common forms of
in transcriptional regulation, or, alternatively, the impor-
breast and ovarian cancer, and the critical physiological tance of histone modification in enabling access to chro-
function of the BRCA1 and BRCA2 proteins. matin and DNA repair, will require further studies. In this
Both BRCA1 and BRCA2 encode large proteins of regard, the effect of EMSY overexpression on the rate
uncertain function. BRCA1 has been implicated in multi- of RAD51-dependent homologous recombination will be
ple cellular processes, including homologous recombi- particularly informative for models of BRCA2 function.
nation, transcription-coupled repair, transcriptional acti- Most interesting is the observation by Hughes-Davies
vation, and, most recently, X chromosome inactivation. et al. that EMSY may be independently targeted by ge-
A BRCA1-BARD1 heterodimer mediates ubiquitin conju- netic events during sporadic breast and ovarian tumori-
gation, a function whose physiological significance is genesis. EMSY maps to chromosome 11q13.5, a locus
supported by the presence of missense mutations in that is amplified in 13% of breast and 17% of ovarian
the BRCA1 ring domain that binds to BARD1, as well cancers (reviewed in Schuuring, 1995). Identification of
as by rare mutations within BARD1 itself (Thai et al., the specific gene targeted by chromosomal amplifica-
1998). Also rare, but functionally significant, are muta- tion is notoriously difficult, all the more within the gene-
tions in the BRCA1-associated helicase BACH1, which rich chromosome 11q13.5 locus. Multiple genes appear
is likely to contribute to BRCA1 function (Cantor et al., to drive amplification at that locus, including Cyclin D1
2001). In contrast, the function of BRCA2 appears to be and EMSI (encoding the actin binding protein cortactin).
somewhat more straightforward. Its direct interaction Supporting a specific role for EMSY, Hughes-Davies et
with RAD51, an essential component of the homologous al. describe one breast cancer cell line in which EMSY
recombination machinery, strongly implies a role in the is amplified more than 5-fold in the absence of Cyclin
repair of double-strand breaks in DNA (Sharan et al., D1 amplification, and in which only the EMSY transcript
1997). Consistent with this, cultured BRCA2-deficient within the amplicon is overexpressed compared with a
cells demonstrate characteristic abnormalities in chro- control cell line. Extending these studies to two very
mosome structure and evidence of genomic instability large collections of sporadic breast cancers analyzed
(Patel et al., 1998). BRCA2 also binds stoichiometrically either by Southern blotting (875 cases) or by FISH (551
cases), they demonstrate EMSY amplification in 7%–to DSS1, a protein of unknown function; it resides within
Cell
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13% of cases (3%–5% without associated Cyclin D1 loss of BRCA genes in familial cases. The mechanistic
amplification). In sporadic ovarian cancer, increased implications of the BRCA2-EMSY interactions remain to
EMSY gene copy numbers were observed in 17% of 360 be fully defined, and demonstration that EMSY over-
cases (10% independent of Cyclin D1 amplification). In a expression is sufficient to drive tumorigenesis will be
panel of tumors representing diverse histologies, EMSY essential before we can conclude that it encodes a
gene amplification was present in 1/5 hepatocellular proto-oncogene involved in the maintenance of geno-
cancers and in 1/7 melanomas. mic integrity. However, the combination of elegant bio-
Taken all together, these observations suggest that chemical and genetic analyses of this novel BRCA2-
EMSY overexpression through amplification may con- associated protein provides important new insight into
tribute to tumorigenesis in a subset of sporadic cancers. a pathway that is disrupted in human breast and ovar-
Whether EMSY overexpression is sufficient to drive tu- ian cancers.
morigenesis is difficult to ascertain solely on the basis
of such genetic studies, and will require demonstration Daniel A. Haber
of oncogenic effects in experimental systems. Cell-based Massachusetts General Hospital Cancer Center
transformation assays are not easily adaptable to mea- Harvard Medical School
suring the effects of genes that regulate genomic stabil- Charlestown, Massachusetts 02129
ity, whose effects on cellular proliferation may be indi-
rect. However, mice with attenuated BRCA2 develop Selected Reading
lymphoid tumors (Patel et al., 1998), and tissue-specific
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that Cyclin D1 is a specific target of gene amplification
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ments will be required to confirm the role of EMSY in tu-
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prognosis, a median disease-free survival of 6.4 years Schuuring, E. (1995). Gene 159, 83–96.
in breast cancer cases with gene amplification, versus Sharan, S.K., Morimatsu, M., Albrecht, U., Llim, D., Regel, E., Dinh,
14 years in cases with diploid gene copy numbers (p  C., Sands, A., Eichele, G., Hasty, P., and Bradley, A. (1997). Nature
0.002). This difference was most prominent in cases 386, 804–810.
without evidence of metastases to regional lymph nodes Thai, Th., Du, F., Tsan, J.T., Jin, Y., Phung, A., Spillman, M.A., Massa,
H.F., Mul, C.Y., Ashfaq, R., Mathis, J.M., et al. (1998). Hum. Mol.at the time of diagnosis, and it was not evident in those
Genet. 7, 195–202.with positive lymph nodes (possibly reflecting the pres-
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ing 1995), and while the current analysis did not exclude
cases with concomitant amplification of Cyclin D1 or
EMSI, multivariate analysis indicated that the link be-
tween prognosis and gene amplification reached statis- Rad53: A Controller Ensuringtical significance for EMSY, but not for Cyclin D1. These
observations are unlikely to have immediate clinical im- the Fine-Tuning of Histone Levels
pact, since other features currently used in clinical prac-
tice, such as tumor size, were more informative than
EMSY amplification status, and other important charac-
Checkpoint proteins are activated in response to ge-teristics, such as tumor histology and grade were not
notoxic insults or replication stress to maintain ge-studied. However, comparing the clinical and molecular
nome integrity. Their function is believed to dependfeatures of breast cancers with EMSY amplification with
largely on the detection of the DNA damage or defectsthose resulting from inactivation of BRCA1 or BRCA2
occurring during replication fork progression.may prove to be very interesting. While BRCA2 null
breast cancers do not appear to have distinct histopath-
In this issue of Cell, Gunjan and Verreault (2003) revealological or clinical characteristics, those associated with
a novel function for the S. cerevisiae checkpoint kinaseinactivation of BRCA1 are more commonly poorly differ-
Rad53 as a participant in a surveillance mechanism thatentiated, estrogen-receptor negative, and exhibit some
prevents the accumulation of nonnucleosomal histonescharacteristic histopathological features (reviewed in
in the cell.Osin and Lakhani, 1999).
It is widely accepted that, upon DNA damage andIn sum, the studies of Hughes-Davies and coworkers
replication stress, checkpoint responses arrest the cellwill generate considerable interest by their suggestion
cycle to provide additional time for repair and thus con-that overexpression of EMSY in some sporadic breast
and ovarian cancers may be functionally equivalent to tribute to genome integrity (Zhou and Elledge, 2000). In
